Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways

Myostatin is a crucial cytokine that is widely present in skeletal muscle and that negatively regulates the growth and development of muscle cells. Recent research has shown that myostatin might play an essential role in bone metabolism. In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin...

Full description

Bibliographic Details
Main Authors: Xin Zhi, Qian Chen, Shaojun Song, Zhengrong Gu, Wenqiang Wei, Huiwen Chen, Xiao Chen, Weizong Weng, Qirong Zhou, Jin Cui, Liehu Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.565163/full
_version_ 1818821906618384384
author Xin Zhi
Qian Chen
Shaojun Song
Zhengrong Gu
Wenqiang Wei
Huiwen Chen
Xiao Chen
Weizong Weng
Qirong Zhou
Jin Cui
Liehu Cao
author_facet Xin Zhi
Qian Chen
Shaojun Song
Zhengrong Gu
Wenqiang Wei
Huiwen Chen
Xiao Chen
Weizong Weng
Qirong Zhou
Jin Cui
Liehu Cao
author_sort Xin Zhi
collection DOAJ
description Myostatin is a crucial cytokine that is widely present in skeletal muscle and that negatively regulates the growth and development of muscle cells. Recent research has shown that myostatin might play an essential role in bone metabolism. In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. Overexpression of myostatin promoted osteoclastogenesis and osteoclastogenesis-related markers including c-Src, MMP9, CTR, CK, and NFATc1. Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. Our study indicates that myostatin is a promising candidate target for inhibiting RANKL-mediated osteoclastogenesis and might participate in therapy for osteoporosis, and that the Ccdc50 gene plays a significant role in the regulatory process.
first_indexed 2024-12-18T23:15:38Z
format Article
id doaj.art-83e7b4557f6045c784db2c8b7f24b605
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-18T23:15:38Z
publishDate 2020-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-83e7b4557f6045c784db2c8b7f24b6052022-12-21T20:48:14ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-11-011110.3389/fphar.2020.565163565163Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK PathwaysXin Zhi0Qian Chen1Shaojun Song2Zhengrong Gu3Wenqiang Wei4Huiwen Chen5Xiao Chen6Weizong Weng7Qirong Zhou8Jin Cui9Liehu Cao10Department of Orthopedics, PLA General Hospital, Beijing, ChinaBasic Medical School, Naval Military Medical University, Shanghai, ChinaDepartment of Emergency, General Hospital of Central Theather Command, Wuhan, ChinaDepartment of Orthopedics, Shanghai Baoshan Luodian Hospital, Shanghai, ChinaDepartment of Orthopedics, Shanghai Baoshan Luodian Hospital, Shanghai, ChinaDepartment of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Orthopedics Trauma, Shanghai Changhai Hospital, Naval Military Medical University, Shanghai, ChinaDepartment of Orthopedics, Shanghai Baoshan Luodian Hospital, Shanghai, ChinaMyostatin is a crucial cytokine that is widely present in skeletal muscle and that negatively regulates the growth and development of muscle cells. Recent research has shown that myostatin might play an essential role in bone metabolism. In RAW264.7 cells and bone marrow monocytes (BMMCs), myostatin activates the expression of the II type receptor ActR II B. Here, we report that myostatin significantly promoted RANKL/M-CSF-induced osteoclastogenesis and activated NF-κB and MAPK pathways in vitro via the Ccdc50 gene. Overexpression of myostatin promoted osteoclastogenesis and osteoclastogenesis-related markers including c-Src, MMP9, CTR, CK, and NFATc1. Specifically, myostatin increased the phosphorylation of Smad2, which led to the activation of NF-κB and MAPK pathways to activate osteoclastogenesis. Ccdc50 was identified as a gene whose expression was highly decreased in osteoclastogenesis upon myostatin treatment, and it could inhibit the function of myostatin in osteoclastogenesis by blocking NF-κB and MAPKs pathways. Our study indicates that myostatin is a promising candidate target for inhibiting RANKL-mediated osteoclastogenesis and might participate in therapy for osteoporosis, and that the Ccdc50 gene plays a significant role in the regulatory process.https://www.frontiersin.org/articles/10.3389/fphar.2020.565163/fullosteoclastogenesismyostatinCcdc50Receptor activator of NF-κB ligandNF-κB
spellingShingle Xin Zhi
Qian Chen
Shaojun Song
Zhengrong Gu
Wenqiang Wei
Huiwen Chen
Xiao Chen
Weizong Weng
Qirong Zhou
Jin Cui
Liehu Cao
Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
Frontiers in Pharmacology
osteoclastogenesis
myostatin
Ccdc50
Receptor activator of NF-κB ligand
NF-κB
title Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
title_full Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
title_fullStr Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
title_full_unstemmed Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
title_short Myostatin Promotes Osteoclastogenesis by Regulating Ccdc50 Gene Expression and RANKL-Induced NF-κB and MAPK Pathways
title_sort myostatin promotes osteoclastogenesis by regulating ccdc50 gene expression and rankl induced nf κb and mapk pathways
topic osteoclastogenesis
myostatin
Ccdc50
Receptor activator of NF-κB ligand
NF-κB
url https://www.frontiersin.org/articles/10.3389/fphar.2020.565163/full
work_keys_str_mv AT xinzhi myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT qianchen myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT shaojunsong myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT zhengronggu myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT wenqiangwei myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT huiwenchen myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT xiaochen myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT weizongweng myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT qirongzhou myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT jincui myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways
AT liehucao myostatinpromotesosteoclastogenesisbyregulatingccdc50geneexpressionandranklinducednfkbandmapkpathways